title: Interferon-alpha and -gamma differentially reduce rapid immature T-cell death by contact with HIV-1 carrier cell clones in vitro.
abstract: The non-antigen specific rapid cytotoxic (CT) death of immature TdT+CD4+CD8+ T cells due to contact with HIV-1 carrier T-cell clones we have found recently is a novel phenomenon. The effects of interferons (IFN) on this CT reaction were studied in vitro. Treatment of the HIV-1 carrier clones, referred to as "effectors," with IFN-alpha but not IFN-gamma, or of the susceptible immature TdT+CD4+CD8+ T cells, referred to as "targets," with IFN-gamma but not IFN-alpha, for 24 hr prior to CT testing was found to reduce the CT reaction. Simultaneously, a down-regulated CD8 expression and an up-regulated antigen expression of both major histocompatibility antigen complex class I (MHC-I) and HIV-1 gp120/gp160 in the IFN-alpha treated effector (gp120+CD8+ HPB-ALL/HIV), and/or simultaneously up-regulated antigen expression of both CD8 and MHC-I in the IFN-gamma treated target (CD4+CD8+ HPB-ALL) were found to be associated with reduced CT reaction. However, altered antigen expression in the IFN-gamma treated effectors or IFN-alpha treated targets did not affect the ultimate degree of CT reaction. This study thus suggests a possible therapeutic efficacy of IFN by reducing the direct elimination of the T-cell precursors in HIV-1 infection.
authors.affiliation: Fujisaki Cell Center, Hayashibara Biochemical Laboratories, Inc., Okayama, Japan.
authors.forename: P
authors.initials: P
authors.lastname: Kinzl
authors.forename: T
authors.initials: T
authors.lastname: Otani
authors.forename: R
authors.initials: R
authors.lastname: Benz
authors.forename: J
authors.initials: J
authors.lastname: Minowada
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D002478:Cells, Cultured; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004253:DNA Nucleotidylexotransferase / Q000032:analysis; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D015699:HIV Envelope Protein gp120 / Q000096:biosynthesis; D019302:HIV Envelope Protein gp160 / Q000096:biosynthesis; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000473:pathology
chemical_list: D019380:Anti-HIV Agents; D015704:CD4 Antigens; D016827:CD8 Antigens; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D016898:Interferon-alpha; D007371:Interferon-gamma; D004253:DNA Nucleotidylexotransferase